Search results
Results from the WOW.Com Content Network
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. [3] [4] It is taken by mouth. [3] [4] Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from ...
The use of chemotherapy to treat stomach cancer has no firmly established standard of care. [13] Unfortunately, stomach cancer has not been particularly sensitive to these drugs, and chemotherapy, if used, has usually served to palliatively reduce the size of the tumor, relieve symptoms of the disease, and increase survival time. [13]
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs arise in the smooth muscle pacemaker interstitial cell of Cajal, or similar cells. [2] They are defined as tumors whose behavior is driven by mutations in the KIT gene (85%), [2] PDGFRA gene (10%), [2] or BRAF kinase (rare).
The prognosis for these types of tumors depends heavily on the size of the tumor and the rate of mitosis, however approximately 60 percent of GISTs are diagnosed as benign. [4] Surgery to remove the tumor is the primary treatment method, although imatinib, everolimus, and rapamycin may soon be approved as alternative treatment and management ...
Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and indolent systemic mastocytosis. It is also used for the treatment of tumors due to one specific rare mutation: it is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth ...
Macon artist’s work reflects the pain of chemo, and the joy of being cancer-free. Michael W. Pannell. January 4, 2024 at 11:21 AM. Michael W. Pannell/Special to The Telegraph.
The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed.
Cancer pain treatment aims to relieve pain with minimal adverse treatment effects, allowing the person a good quality of life and level of function and a relatively painless death. [27] Though 80–90 percent of cancer pain can be eliminated or well controlled, nearly half of all people with cancer pain in the developed world and more than 80 ...